



RECEIVED

AUG 10 2001

TECH CENTER 1600/2900

K553
1602

PATENT CASE IN01154K

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
K. Chen *et al.*) Examiner: Not assigned yet
Serial No.:09/825,399) Group Art Unit: Not assigned yet
Filed: April 3, 2001)
) Atty. Docket No.: IN01154K

For: **Macrocyclic NS3-Serine Protease Inhibitors of Hepatitis C Virus Comprising N-Cyclic P2 Moieties**

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

It is requested that the following documents cited in the application, as listed below and in the accompanying form PTO-1449, be considered and made of record.

Documents cited in the Application:

U.S. 5,712,145
WO 89/04669
WO 98/17679
WO 98/22496
WO 99/07734
WO 00/09558
WO 00/09543
EP 381 216

Publications:

Pizzi *et al.* (1994) Proc. Natl. Acad. Sci (USA) 91:888-892
Failla *et al.* (1996) Folding & Design 1:35-42
Kollykhalov *et al.* (1994) J. Virol. 68:7525-7533
Komoda *et al.* (1994) J. Virol. 68:7351-7357
Landro *et al.* (1997) Biochem. 36:9340-9348
Ingallinella *et al.* (1998) Biochem. 37:8906-8914
Llinàs-Brunet *et al.* (1998) Bioorg. Med. Chem. Lett. 8:1713-1718
Martin *et al.* (1998) Biochem. 37:11459-11468
Dimasi *et al.* (1997) J. Virol. 71:7461-7469
Martin *et al.* (1997) Protein Eng. 10:607-614
Elzouki *et al.* (1997) J. Hepat. 27:42-48
BioWorld Today 9(217): 4 (November 10, 1998)
Berenguer *et al.* (1998) Proc. Assoc. Am. Physicians 110(2):98-112
Hoofnagle *et al.* (1997) N. Engl. J. Med. 336:347
R. Zhang *et al.*, Analytical Biochemistry, 270 (1999) 268-275

1



Sali *et al*, *Biochemistry*, 37 (1998) 3392-3401
K. Barlos *et al*, *Int. J. Pept. Protein Res.*, 37 (1991), 513-520
K. Holmber *et al*, *Acta Chem. Scand.*, B33 (1979) 410-412
S. Agrawal *et al*, "Development and Characterization of Hepatitis C Virus Serine Protease Cell-based Trans-Cleavage Assay", *Hepatology* Supplement to Volume 30 (No. 4, Part 2, October 1999), Abstract No. 615 (Proceedings of AASLD 50th Annual Meeting, Dallas, Texas, November 5-9, 1999).

The submission of these documents is not to be presumed as an admission that these documents are prior art. The documents are being furnished solely for their possible utility in the examination of the present case. Since no Office Action has issued on the merits of this case, Applicants believe that no fee is due at this time. If, however, any fees are due, the Office may charge such fees to Deposit Account No. 19-0365.

If the Examiner has any questions, the Examiner is invited to contact the undersigned.

August 6, 2001
Schering-Plough Corporation
2000 Galloping Hill Road
Patent Department, K-6-1,1990
Kenilworth, NJ 07033
Tel: (908) 298-5068
Fax: (908) 298-5388

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on

August 6, 2001

Palaiyur S. Kalyanaraman
Registered Representative

P. S. Kalyanaraman 8/6/2001

Signature and Date of Signature

Respectfully submitted,

Palaiyur S. Kalyanaraman
Attorney for Applicants
Reg. No. 34,634



RECEIVED

AUG 10 2001

TELE CENTER 1600/2900

Sheet 1 of 1

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:
IN01154K

SERIAL NO.:
09/825,399

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

APPLICANT:
CHEN, et al

FILING DATE:
April 3, 2001

GROUP:
To Be Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
AA	5,712,145					
AB						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	YES	NO
AC	WO 89/04669							
AD	WO 98/17679							
AE	WO 98/22496							
AF	WO 99/07734							
AG	WO 00/09558							
AH	WO 00/09543							
AI	EP 381 216							
AJ								

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AK	Pizzi, (1994) Proc. Natl. Acad. Sci(USA) 91:888-892
AL	Failla (1996) Folding & Design, 1:35-42
AM	Kollykhalov(1994) J. Virol., 68:7525-7533
AN	Komoda(1994) J. Virol. 68:7351-7357
AO	Landro (1997) Biochem. 36:9340-9348
AP	Ingallinella (1998) Biochem. 37:8906-8914
AQ	Llinas-Brunet(1998)Bioorg. Med. Chem. Lett. 8:1713-1718
AR	Martin (1998) Biochem. 37:37:11459-11468
AS	Dimasi(1997) J. Virol. 71:7461-7469
AT	Martin(1997) Protein Eng. 10:607-614
AU	Elzouki(1997) J. Hepat. 27:42-48
AV	BioWorld Today 9(217): 4(November 10, 1998)
AW	Berenguer(1998)Proc. Assoc. Am. Physicians,110(2):98-112
AX	Hoofnagle(1997) New England Journal of Medicine 336:347
AY	Zhang (1999) Analytical Biochemistry 270:268-275
AZ	Sali(1998) Biochemistry 37:3392-3401
BA	Barlos (1991) Int. J. Pept. Protein Res. 37:513-520
BB	Holmberg(1979)Acta Chem. Scand B33:410-412
BC	Agrawal(1999) Hepatology Supplement to Vol. 30“Development and Characterization of Hepatitis C Virus Serine Protease Cell-based Trans-Cleavage Assay”
BD	Hughes (1992) Org. Reactions 42:335
BE	Heck (1989) Org. Reactions 27:345-390

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.